AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg

News & Events



AmoyDx to Exhibit at ESMO Asia Congress 2022

Amoy Diagnostics will be in the ESMO Asia Congress 2022, held in person in Singapore from December 2-4. 

News & Events



AmoyDx^® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS^® (Sotorasib)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyD

News & Events



MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t

News & Events



Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx^® Pan Lung Cancer PCR Panel (the “

News & Events



Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel

TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am

News & Events



AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan

Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph

News & Events



AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio

News & Events



AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market

Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio

News & Events



AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)

TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the

News & Events



AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i

News & Events



AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market

Xiamen, China, March 12, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) and Haihe Biopharma announced that they signed an agreement to use the MET mutation detection kit of AmoyDx as Companion Diagnostic (CDx) assay supporting the registration o

News & Events



AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market

Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx

News & Events



AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market

Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.

News & Events



MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

News & Events



Pan Lung Cancer PCR Panel

PRODUCTS



Pan Lung Cancer PCR Panel

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-CE

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-CE (QS5)

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-RUO (LC480 z480)

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-RUO (QS5)

DOWNLOAD



AmoyDx® Pan Lung Cancer Detection Reagent (V2) - (for Color Compensation)-B1.0-J-12T

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel - Innovative Multi-gene Testing for NSCLC by qPCR

Speaker: Paul Huang (AmoyDx), Matthias Mueser (AmoyDx), Daniel Giner (AmoyDx), Agata Page (Unilabs)

Videos



AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg

News & Events



AmoyDx to Exhibit at ESMO Asia Congress 2022

Amoy Diagnostics will be in the ESMO Asia Congress 2022, held in person in Singapore from December 2-4. 

News & Events



AmoyDx^® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for LUMAKRAS^® (Sotorasib)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyD

News & Events



MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t

News & Events



Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx^® Pan Lung Cancer PCR Panel (the “

News & Events



Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel

TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am

News & Events



AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan

Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph

News & Events



AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio

News & Events



AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market

Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio

News & Events



AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)

TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the

News & Events



AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i

News & Events



AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market

Xiamen, China, March 12, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) and Haihe Biopharma announced that they signed an agreement to use the MET mutation detection kit of AmoyDx as Companion Diagnostic (CDx) assay supporting the registration o

News & Events



AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market

Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx

News & Events



AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market

Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.

News & Events



MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

News & Events



Pan Lung Cancer PCR Panel

PRODUCTS



Pan Lung Cancer PCR Panel

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-CE

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-CE (QS5)

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-RUO (LC480 z480)

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel-P1.1-8T-RUO (QS5)

DOWNLOAD



AmoyDx® Pan Lung Cancer Detection Reagent (V2) - (for Color Compensation)-B1.0-J-12T

DOWNLOAD



AmoyDx® Pan Lung Cancer PCR Panel - Innovative Multi-gene Testing for NSCLC by qPCR

Speaker: Paul Huang (AmoyDx), Matthias Mueser (AmoyDx), Daniel Giner (AmoyDx), Agata Page (Unilabs)

Videos

